The Patent Finder
GP

Gilgamesh Pharmaceuticals, Inc.

First filing 2021
OverviewNotableFeesChangesFamiliesPatent listSources & methods

Four patents currently held, every record listed here

2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

The next term ends in Feb 2041. from the record

Of the 2 now held by other companies, 2 name Gilgamesh Pharma Inc. as their current owner. Each row says so.

Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Feb 2041
Next term end
3
Patent families

When these terms end

Each bar runs from grant to computed term end. 2022 to 2043.
US 11,344,510 Arylcyclohexylamine Derivatives and Their Use in the Treatment of Psychiatric Disorders Dec 28, 2040
US 11,440,879 Methods of Treating Mood Disorders no later than Feb 18, 2041
US 12,534,425 Phenalkylamines and Methods of Treating Mood Disorders Mar 31, 2042
US 12,157,722 Crystalline Hydrochloride Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine Sep 14, 2043
US 12,180,158 Crystalline Fumarate Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine Sep 14, 2043
US 12,129,234 Crystalline Salts of N-ETHYL-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine Sep 14, 2043
202620302034203820422043
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
19 pending applications: term is not computable until grant.Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know

Fee deadlines

No maintenance fee falls due on this company's record before Nov 17, 2027.

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

What they patent

Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.

Patents held now

Soonest term end first.

Showing 1 to 4 of 4

PatentTitleStatusExpiresConfidence
US 11,440,879Methods of Treating Mood Disorders
In force
 · Low confidence
In forceLow confidence
US 12,129,234Crystalline Salts of N-ETHYL-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
In force
 · High confidence
In forceHigh confidence
US 12,157,722Crystalline Hydrochloride Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
In force
 · High confidence
In forceHigh confidence
US 12,180,158Crystalline Fumarate Salts of N-ETHYL-2-(5-Fluoro-1H-INDOL-3-YL)-N-METHYLETHAN-1-Amine
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 4: 2 patents in force now held by others · 19 applications pending · 4 applications abandoned. List them

Sources and methods

Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
1 terminal disclaimer is on file with no resolved reference. No cap is applied and none is guessed
1 computed term date comes from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited